Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

10,628 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,472
Recruiting: 1,283
Ph III recruiting: 130
Growth YoY: +4.1%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,642)

clinicaltrialsPublishedShowing 351–400 of 852 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03277729	A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas	active not recruiting	Phase 1 / Phase 2	53	Fred Hutchinson Cancer CenterOTHER	1	Jun 22, 2026	clinicaltrials
NCT04545762	Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma	recruiting	Phase 1	36	C. Babis AndreadisOTHER	1